You don't need a science degree to read a clinical study — you need to know what four or five numbers mean. Here's the Q-Actin® cucumber-extract research in plain English, limits included, so you can judge it yourself instead of taking anyone's word for it. For context on why joints change after 40 in the first place, see our pillar guide.
What Q-Actin® is
Q-Actin® is a standardized extract of cucumber (Cucumis sativus), concentrated to contain over 1% of an iminosugar amino acid called idoBR1. It's the studied active behind the joint research below, and it's patented (US Patent 9,326,977 B2) — though a patent describes a composition, it is not evidence that something works. The studied daily dose is small: 20 mg.
There are five published human studies on the ingredient. Three of them are broken down below.
Study one: the 180-day head-to-head (Nash et al., 2018)
Who: adults with moderate knee osteoarthritis. What: 20 mg/day Q-Actin® versus 2,700 mg/day glucosamine-chondroitin. How long: 180 days. How measured: the WOMAC joint score, a validated questionnaire.
The finding: the Q-Actin® group's WOMAC score improved by 70.3%, versus 33.7% for glucosamine-chondroitin (PMC6207263). No adverse events were reported. Individual results may vary.
What's good about it: it was randomized and double-blind (neither participants nor researchers knew who got what), it ran long enough for a slow process, and it used a validated instrument.
What limits it — and this matters: it was sponsor-funded; it had no placebo arm, because both groups took an active supplement, so it shows how the two moved relative to each other and not how either compares with taking nothing; and it is a pooled multicentre pilot rather than a large confirmatory trial. A 70.3% figure with no placebo group is a different kind of number from a 70.3% figure with one.
Study two: the 60-day placebo-controlled trial (Hausenblas et al., 2025)
Who: 80 adults with mild-to-moderate joint discomfort. What: 20 mg/day Q-Actin® versus placebo. How long: 60 days. The finding: a 31.79% WOMAC improvement from baseline, with no adverse events (published in Cureus). Individual results may vary.
What "from baseline" means here, and why we're spelling it out: that 31.79% is a within-group change — the same people, start versus finish. It is not the amount by which the supplement beat the placebo. And the study's pre-registered primary measure did not reach statistical significance, which means the main question the researchers set out to answer was not answered in the affirmative. The study having a placebo group is genuinely a strength of its design; it did not produce a significant primary result.
We publish this one because a brand that shows you only the studies that landed is not showing you evidence.
Study three: the 12-week wellbeing study (Lloyd et al., 2025)
Who: 47 healthy adults aged 50–78. What: 20 mg/day versus placebo. How long: 12 weeks. The finding: alongside physical-function measures, researchers noted signals on finger dexterity and a rise in urinary melatonin metabolites that correlated with self-reported sleep-quality improvement (Frontiers in Nutrition, PubMed 40421033). A correlation with a self-reported measure is a signal worth noting, not a demonstrated effect. Individual results may vary.
What the research says
Notice the consistency: all three studies above used the same 20 mg daily dose. That's important, because it means a product dosed at 20 mg is dosed to match the research — not to a marketing round-number. If a joint product cites these studies but contains a different dose, the citation is doing less than it appears. Note too that no Q-Actin® trial has been run fully independently of the ingredient's own commercial backers, and that all of this research is on the active ingredient rather than on any finished product.
What the studies do NOT say
Being honest about the evidence is part of trusting it. These studies do not show that Q-Actin® "cures" or "treats" any disease — they measured changes on joint-comfort and function scales in supplement research. The sleep signal in the 12-week study was a trend supported by a biomarker, not a definitive sleep finding. The 60-day study's primary measure missed. And the 180-day head-to-head had no placebo group. Good science states its limits, and so should any brand citing it.
That's the whole reason we built a gummy dosed to the 20 mg used across these three trials and put the citations on the page. Want to understand the scoring system these studies rely on? See WOMAC scores explained. Curious how this compares to the old standard? Read Q-Actin® vs glucosamine.
Frequently Asked Questions
What dose of Q-Actin® was used in the studies?
All three studies described above used 20 mg per day. A product dosed at 20 mg matches the research.
Were the Q-Actin® studies placebo-controlled?
Not all of them. The 2018 head-to-head had no placebo arm — it compared Q-Actin® against glucosamine-chondroitin, and it was sponsor-funded. The Hausenblas 2025 and Lloyd 2025 studies did use placebo groups; in Hausenblas, the pre-registered primary measure did not reach statistical significance. Individual results may vary.
Do these studies prove Q-Actin® treats arthritis?
No. They measured changes on joint-comfort and function scales. Supplements are not treatments for disease, and these studies should not be read as disease-treatment claims.
Written by Dr. Mohammed Hawa, DHA, Founder of VyVa.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult your healthcare provider before beginning any supplement, particularly if you are pregnant, breastfeeding, under 18, or taking prescription medication.
